Chronic prostatitis does not influence urinary PCA3 score

Prostate

Volumn 72, Issue 5, 2012, Pages 549-554

  Vlaeminck Guillem, Virginie ^a,b   Bandel, Marion ^b   Cottancin, Martine ^a   Rodriguez Lafrasse, Claire ^a,b   Bohbot, Jean Marc ^c   Sednaoui, Patrice ^c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSTITUT ALFRED FOURNIER   (France)

Author keywords

chronic prostatitis; prostate cancer; prostate cancer antigen 3; urine

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN PCA3; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC PROSTATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC TEST; ERYTHROCYTE COUNT; ESCHERICHIA COLI; HAEMOPHILUS PARAINFLUENZAE; HUMAN; LEUKOCYTE COUNT; MALE; MEARES STAMEY FOUR GLASS LOCALIZATION TEST; PELVIS PAIN SYNDROME; PEPTOSTREPTOCOCCUS; PEPTOSTREPTOCOCCUS ANAEROBIUS; PRIORITY JOURNAL; RNA TRANSCRIPTION; SCORING SYSTEM; STREPTOCOCCUS; URETHRITIS; URINALYSIS; URINE CYTOLOGY;

ADULT; ANTIGENS, NEOPLASM; CHRONIC DISEASE; HEMATURIA; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATITIS; TUMOR MARKERS, BIOLOGICAL; URINE; YOUNG ADULT;

EID: 84857505354     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21457     Document Type: Article

References (30)

1. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB,. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59 (23): 5975-5979.
2. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA,. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62 (9): 2695-2698.
3. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF, Gardiner RA,. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005; 114 (6): 950-956.
4. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H,. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52 (6): 1089-1095.
5. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J,. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179 (4): 1587-1592.
6. Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P,. Urinary prostate cancer 3 test: Toward the age of reason? Urology 2010; 75 (2): 447-453.
7. Marks LS, Bostwick DG,. Prostate cancer specificity of PCA3 gene testing: Examples from clinical practice. Rev Urol 2008; 10 (3): 175-181.
8. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J,. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69 (3): 532-535.
9. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54 (5): 1081-1088.
10. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA,. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44 (1): 8-15.
11. Tinzl M, Marberger M, Horvath S, Chypre C,. DD3PCA3 RNA analysis in urineA new perspective for detecting prostate cancer. Eur Urol 2004; 46 (2): 182-186.
12. Murphy AB, Macejko A, Taylor A, Nadler RB,. Chronic prostatitis: Management strategies. Drugs 2009; 69 (1): 71-84.
13. Habermacher GM, Chason JT, Schaeffer AJ,. Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 2006; 57: 195-206.
14. Meares EM, Stamey TA,. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968; 5 (5): 492-518.
15. Monfort L, Caro V, Devaux Z, Delannoy AS, Brisse S, Sednaoui P,. First neisseria gonorrhoeae genotyping analysis in france: Identification of a strain cluster with reduced susceptibility to Ceftriaxone. J Clin Microbiol 2009; 47 (11): 3540-3545.
16. Jaton K, Bille J, Greub G,. A novel real-time PCR to detect Chlamydia trachomatis in first-void urine or genital swabs. J Med Microbiol 2006; 55 (Pt 12): 1667-1674.
17. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL,. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154 (2 Pt 1): 407-413.
18. Potts JM,. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol 2000; 164 (5): 1550-1553.
19. Kwak C, Ku JH, Kim T, Park DW, Choi KY, Lee E, Lee SE, Lee C,. Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer. Urology 2003; 62 (5): 854-859.
20. Stancik I, Luftenegger W, Klimpfinger M, Muller MM, Hoeltl W,. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol 2004; 46 (6): 760-764.
21. Bozeman CB, Carver BS, Eastham JA, Venable DD,. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002; 167 (4): 1723-1726.
22. Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB,. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol 2005; 174 (1): 161-164.
23. Hochreiter WW,. The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. Andrologia 2008; 40 (2): 130-133.
24. Sandhu JS,. Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis. Curr Urol Rep 2009; 10 (4): 302-306.
25. Sindhwani P, Wilson CM,. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005; 6 (4): 307-312.
26. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M,. Mechanisms of disease: High-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol 2007; 4 (6): 321-332.
27. Galasso F, Giannella R, Bruni P, Giulivo R, Barbini VR, Disanto V, Leonardi R, Pansadoro V, Sepe G,. PCA3: A new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study. Arch Ital Urol Androl 2010; 82 (1): 5-9.
28. Remzi M, Haese A, Van Poppel H, De La Taille A, Stenzl A, Hennenlotter J, Marberger M,. Follow-up of men with an elevated PCA3 score and a negative biopsy: Does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 2010; 106 (8): 1138-1142.
29. Morote J, Rigau M, Garcia M, Mir C, Ballesteros C, Planas J, Raventos CX, Placer J, de Torres IM, Reventos J, Doll A,. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol 2010; 28 (6): 677-680.
30. Woenckhaus J, Fenic I,. Proliferative inflammatory atrophy: A Background: lesion of prostate cancer? Andrologia 2008; 40 (2): 134-137.